Treatment of nonalcoholic fatty liver: Present and emerging therapies

Seminars in Liver Disease

Volumn 21, Issue 1, 2001, Pages 81-88

  Angulo, P ^a   Lindor, K D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Nonalcoholic fatty liver; Treatment

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMIODARONE; ANOREXIGENIC AGENT; BETAINE; CALCIUM ANTAGONIST; CHLOROQUINE; CHOLINE; CLOFIBRATE; CORTICOSTEROID; ESTROGEN; GEMFIBROZIL; METRONIDAZOLE; PERHEXILINE MALEATE; POLYMYXIN B; SALICYLIC ACID DERIVATIVE; TAMOXIFEN; TETRACYCLINE; URSODEOXYCHOLIC ACID;

CLINICAL TRIAL; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG EFFICACY; FATTY LIVER; HUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

EID: 0035085858     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-12931     Document Type: Review

References (56)

1. Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease
2. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity
3. The natural history of nonalcoholic steatohepatitis: A follow up study of forty-two patients for up to 21 years
4. The natural history of nonalcoholic fatty liver: A follow up study
5. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions
6. Alcohol-like liver disease in nonalcoholic. A clinical and histological comparison with alcohol-induced liver injury
7. Nonalcoholic steatohepatitis. A study of 49 patients
8. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: A pilot study
9. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
10. Nonalcoholic steatohepatitis in obesity: A reversible condition
11. Liver morphology and function tests in obesity and during total starvation
12. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass
13. Effect of weight reduction on hepatic abnormalities in overweight patients
14. Hepatic effects of dietary weight loss in morbidly obese patients
15. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
16. Persistent hyperaminotransferasemia resolving after weight reduction in obese children
17. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population
18. Nonalcoholic steatohepatitis in children
19. Very-low-calorie diets for the treatment of obesity
20. A risk-benefit assessment of anti-obesity drugs
21. Appetite-suppressant drugs and the risk of primary pulmonary hypertension
22. Metformin reverses fatty liver disease in obese, leptin-deficient mice
23. Intestinal bypass surgery for morbid obesity. Long term results
24. Jejunoileal bypass as a treatment of morbid obesity
25. Protein supplementation in the management of degenerating liver function after jejunoileal bypass
26. Hepatic steatosis after intestinal bypass. Prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition
27. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition in rats
28. Choline deficiency: A cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation
29. Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in rat
30. A possible beneficial effect of metronidazole in reducing TPN-associated liver function derangements
31. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
32. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: Results of a prospective clinical controlled trial
33. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis
34. Dietary Betaine promotes generation of hepatitic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration
35. Betaine for patients with nonalcoholic steatohepatitis: A promising new agent
36. Treatment of non-alcoholic steatohepatitis with N-acetylcysteine
37. Long- and short-term d-alpha-tocopherol supplementation inhibits liver collagen alpha-1(I) gene expression
38. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
39. Acute and chronic hepatic steatosis lead to in vivo lipid petoxidation in mice
40. Reactive oxygen species activate the transcription factor NF-kB in the liver by induction of lipid peroxidation
41. Injury produce by free fatty acids to lysosomes and mitochondria in cultures heart muscle and endothelial cells
42. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation
43. Herbal products for liver diseases. A therapeutic challenge for the new millennium
44. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis
45. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion
46. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis. A pilot study
47. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohapatitis
48. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
49. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis
50. Hepatic iron and nonalcoholic fatty liver disease
51. Phlebotomy reduces transaminase levels in patients with non-alcoholic steatohepatitis
52. Effect of phlebotomy on non-alcoholic steatohepatitis (NASH)
53. Prevalence of insulin resistance in metabolic disorders
54. Insulin resistance-associated hepatic iron overload
55. Pilot study of troglitazone (Rezulin) for nonalcoholic steatohepatitis
56. Hepatic dysfunction associated with troglitazone